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Abstract
Background There is currently no consensus on the criteria
for inclusion of new bariatric procedures into routine clinical
practice. This study canvasses bariatric surgeons in an attempt
to define these criteria.
Methods Bariatric Surgeons from around the world were in-
vited to participate in a questionnaire-based survey on
SurveyMonkey ®.
Results 396 bariatric surgeons, 337 International Federation
for the Surgery of Obesity and Metabolic Disorders (IFSO)
members, took the survey. Five clinical studies conducted
under the strict monitoring of an Institutional Review Board
would satisfy most surgeons (67.7 %, n = 266). When asked
regarding the number of patients in these studies, a cumulative
number of 500 patients would satisfy 64.5 % (n = 255) of the
surgeons. Most respondents regarded endorsement by their
national society and IFSO as ‘very important’ or ‘extremely
important’. An overwhelming 74.4 % (n = 294) felt that every
new procedure should undergo a randomized comparison
against one of the established alternatives like Roux-en-Y
Gastric Bypass or Sleeve Gastrectomy.
Conclusion Evaluation of a new bariatric procedure in at least
5 adequately supervised clinical studies (four of which must
be randomized comparisons with one of the existing alterna-
tives) reporting at least 5 years results on a minimum of 500
patients would satisfy majority of bariatric surgeons for the
inclusion of a new bariatric procedure into clinical practice.
The findings of this survey are simply aimed at starting a
discussion on this topic and cannot be used to influence the
ground reality until an international consensus can be reached
amongst experts.
Keywords Experimental procedures . New procedures .
Bariatric surgery . Obesity surgery . One anastomosis gastric
bypass . Mini gastric bypass
Introduction
Driven by a desire to develop safer, better, and more durable
alternatives to the existing options, bariatric Surgery is
witnessing innovation at a rapid rate. There is however cur-
rently no consensus on the criteria for inclusion of a new
bariatric procedure into routine clinical practice. On one hand,
this risks adoption of new experimental procedures before
demonstrated clinical outcomes; on the other, this may lead
to undue delays even in the face of robust data. In the absence
of clear guidance, endorsement decisions by national and in-
ternational bariatric societies could also be arbitrary depend-
ing on the views of the position holders.
Surgical innovation generally poses a number of ethical
dilemmas [1]. But when it comes to bariatric surgery, the
challenge is even more intimidating, as there are potentially
a large number of outcome measures each procedure could be
assessed upon [2]. Adoption of new procedures into clinical
practice before demonstrated outcomes may put patients at
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unnecessary risk as well as bring the specialty into disrepute.
This has led many authoritative voices to express caution [3,
4] against unregulated over enthusiastic innovation.
Bariatric surgeons are however not new to moral and eth-
ical challenges [5, 6]. Over the last couple of decades, the
specialty has fought off a few such dilemmas to come to be
recognized as a serious scientific discipline. Though it would
appear contradictory, development of clear processes that a
new bariatric surgical procedure should go through prior to
its acceptance into the mainstream bariatric practice will even-
tually facilitate innovation and protect both patients and
surgeons.
The purpose of this study was to survey the opinion of the
global community of bariatric and metabolic surgeons on the
process of development of new bariatric and metabolic proce-
dures and criteria that should be met before a new bariatric or
metabolic procedure could be introduced into routine clinical
practice.
Methods
A questionnaire-based survey (https://www.surveymonkey.
co.uk/r/ZCSMV87) was conducted of the global community
of bariatric and metabolic surgeons. Surgeons were invited to
take the survey on SurveyMonkey ® starting on 12th March’
2016. The link to the survey was freely shared on the social
media, email chat group of surgeons, and through personal
networks. An email was also sent to presidents of all the
national bariatric societies affiliated to International
Federation for the Surgery of Obesity and Metabolic
Disorders (IFSO) for circulation amongst their membership.
The survey was closed for analysis on 20th April 2016. Basic
descriptive statistics was used. This study was only designed
to survey the opinion of bariatric surgeons on this topic. It is
not an attempt at building consensus.
The choices offered in the survey were felt to be the most
logical options by the authors. To ensure that respondents
could also enter other options, we also provided a free text
option in each and every question.
Results
A total of 422 individuals participated in the survey. Out of
these 396 described themselves as a bariatric/metabolic sur-
geon. Further analysis was only carried out on these 396 indi-
viduals only and the data for others was discarded. Table 1
shows the country of origin of the respondents with the per-
centage and the actual numbers.
Of these 337 (85.5 %) surgeons were members of
IFSO and 95.7 % (378/395) were members of a national
society affiliated to IFSO. A total of 139 (36.1 %)
Table 1 Country of Origin of Respondents in Alphabetical Order
Country of Origin Percentage Number of
Responses
Argentina 2.3 % 9
Australia 3.8 % 15
Austria 0.5 % 2
Belgium 2.8 % 11
Brazil 9.2 % 36
Canada 0.3 % 1
Chile 3.1 % 12
China 0.3 % 1
Colombia 2.8 % 11
Czech Republic 1.0 % 4
Dominican Republic 0.8 % 3
Egypt 2.6 % 10
France 3.6 % 14
Germany 1.3 % 5
Greece 1.5 % 6
India 12.0 % 47
Israel 0.5 % 2
Italy 6.9 % 27
Jordan 0.3 % 1
Kuwait 0.8 % 3
Lebanon 1.5 % 6
Mexico 2.8 % 11
Netherlands 1.0 % 4
New Zealand 0.5 % 2
Nicaragua 0.3 % 1
Norway 0.5 % 2
Pakistan 0.3 % 1
Panama 0.3 % 1
Paraguay 0.5 % 2
Peru 0.5 % 2
Philippines 0.3 % 1
Poland 0.8 % 3
Portugal 3.6 % 14
Republic of Korea 0.3 % 1
Romania 0.3 % 1
Russian Federation 0.8 % 3
Saudi Arabia 1.3 % 5
Singapore 0.5 % 2
South Africa 0.3 % 1
Spain 5.6 % 22
Sweden 1.5 % 6
Switzerland 1.0 % 4
Turkey 0.3 % 1
Ukraine 0.8 % 3
United Arab Emirates 1.8 % 7
United Kingdom 11.0 % 43
United States of America 5.4 % 21
Venezuela (Bolivarian Republic of) 0.3 % 1
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respondents regarded themselves as a ‘key opinion mak-
er’ and a further 81 (21 %) respondents were not sure if
they were a key opinion maker whereas 165 (42.8 %)
respondents did not belong to this category. A ‘key opin-
ion maker’ was loosely defined as somebody with a po-
sition on the national/international organizations or com-
mittees, professorships, serious researcher etc. Amongst
the survey respondents were 4 IFSO presidents, 3 presi-
dents of American Society for Metabolic and Bariatric
Surgery (ASMBS), and 4 presidents of national societies.
Number of Cohort Studies, Patients, and Follow up
Table 2 gives an idea of the number of ‘studies’ that the re-
spondents felt should be conducted on human subjects under
careful monitoring of an Institutional Review Board (IRB)
before a new procedure can be regarded as an accepted treat-
ment option. A significant 67.68 % (n = 266/393) of the re-
spondents felt ≤5 studies were sufficient for this purpose, and
another 12.97 % (n = 51/393) surgeons felt that a minimum of
10 studies should be required. Interestingly 9.41 % (n = 37/
393) surgeons wanted ≥20 studies.
Table 3 presents data on the number of ‘patients’ that the
respondents felt any new procedure must first be performed
on, under the careful monitoring of an IRB before it can be
regarded as an accepted treatment option. Out of 395 respon-
dents who answered this question, 64.5 % (n = 255) felt that
any new procedure must first be performed on ≤500 proce-
dures before it can be regarded as an accepted treatment. Only
11.9 % of the respondents (n = 47) felt that every new proce-
dure should first be performed on >1000 patients.
Table 4 details the mandatory follow-up period under care-
ful monitoring. Most of the respondents would be satisfied
with 5 years follow-up (n = 336, 85.5 %). Interestingly 28
(7.1 %) respondents wanted the follow-up duration to be
10 years or longer.
Endorsement by National Society and IFSO
Figure 1 gives us an idea of how important is the endorsement
by the respondent’s national society to themwhere ‘Extremely
Important’ meant that the respondent would not perform a
new procedure without the endorsement of his/her national
society. Out of 393 respondents who answered this question,
36.1 % (n = 142) and 41.7 % (n = 164) respondents regarded
endorsement by their national society as ‘extremely impor-
tant’ and ‘very important’ respectively.
Figure 2 presents data on the importance of IFSO endorse-
ment for respondents. Out of 394 respondents who answered
this question, 29.4 % (n = 116) and 44.4 % (n = 175) respon-
dents regarded IFSO endorsement as ‘extremely important’
and ‘very important’ respectively.
Randomized Controlled Trials
An overwhelming 74.4 % (n = 294) felt that every new pro-
cedure should first be examined against one of the standard
bariatric procedures in a randomized setting. Only 15.7 %
(n = 62) did not feel it to be a necessary prerequisite and
9.9 % (n = 39) were ‘not sure’.
Those respondents who wanted such randomized compar-
isons were then asked further questions regarding which








1 7 1.78 %
2 28 7.12 %
3 76 19.34 %
4 19 4.83 %
5 136 34.61 %
>5 127 32.32 %
Table 3 Number of Patients under careful monitoring of an
Institutional Review Board needed
Number of Patients Under




1–50 21 5.3 %
51–100 78 19.7 %
101–250 77 19.5 %
251–500 79 20.0 %
501–1000 93 23.5 %
>1000 47 11.9 %
Table 4 Follow-Up Duration under careful monitoring of an
Institutional Review Board needed
Mandatory Follow Up Under




< 6 months 0 0.0 %
6–12 months 11 2.8 %
12–18 months 26 6.6 %
18–24 months 65 16.5 %
2–3 years 77 19.6 %
3–4 years 24 6.1 %
4–5 years 133 33.8 %
> 5 years 57 14.5 %
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procedure should a new procedure be compared against it and
how many such comparisons were needed. A total of 317
respondents answered the question on the most appropriate
existing procedure for randomized comparison with the new
one. Respondents were allowed to select more than one pro-
cedure. Out of these, 267 respondents (84.23 %) felt every
new procedure should be examined against Roux-en-Y
Gastric Bypass (RYGB); 174 (54.9 %) said Sleeve
Gastrectomy (SG), 64 (20.2 %) said One Anastomosis
(Mini) Gastric Bypass and 25 (7.9 %) said Gastric Banding.
Thirty (9.4%) respondents wanted a new procedure compared
against ‘other procedures’ like Biliopancreatic Diversion/
Duodenal Switch (7/317), Gastric Plication (5/317), Ileal
Transposition etc.
When asked regarding the number of Randomized
Controlled Trials, 309 respondents answered the question.
The majority of these respondents (54.4 %, n = 168) would
be satisfied with 4 or less randomized studies. Another large
group (30.7 %, n = 95) would like to have 5 such randomized
comparisons. A smaller percentage (14.9 %, n = 46) wanted
more than 5 randomized studies. Half of these respondents
(n = 23, 7.5 %) wanted 10 trials.
A total of 317 respondents answered the question regarding
which outcome measures should be studied in such random-
ized comparisons. Respondents were allowed to select more
than one response. Table 5 presents the outcome measures
with the number of respondents voting for it.
Comments
We also asked respondents to provide Bany other comment^ at
the end of the questionnaire. An attempt was then made to
identify and develop important themes from these comments
using a deductive approach.
1. One of the themes that emerged was that the quality of the
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Not at all Important
Fig. 2 How Important is
Endorsement by IFSO?
876 OBES SURG (2017) 27:873–880
BEven one adequately powered, multi-centre randomized
controlled trial with adequate follow-up should be
enough^.
BThe studies have to come from proper academic centres^
again emphasizing that the quality of the study was as
important as the quantity.
2. Some respondents highlighted the necessity for prior an-
imal studies before human trials.
BPreclinical animal model studies are needed before hu-
man studies^.
3. A number of surgeons were concerned regarding lack of
monitoring of the studies.
BToo many people are experimenting in Bariatric
Surgical procedures.^ Table 6 presents some other useful
comments (edited) relevant to the survey.
The Questionnaire
Finally, Table 7 provides a brief questionnaire with numbers
of individual responses for each question.
Discussion
Despite authoritative voices expressing concerns against un-
ethical behaviour and unregulated innovation in the field of
bariatric surgery [3, 4], there is as yet no attempt in scientific
literature to define the process for inclusion of a new proce-
dure into the mainstream bariatric practice. This survey is the
first attempt to start a discussion on the proposed criteria for
such benchmarking.
For a relatively small specialty, this survey of 396
bariatric surgeons from around the world represents a
large sample. As can be seen in Table 1, respondents in
this study represent almost every single country where
bariatric surgery is performed. Though numbers of re-
spondents are not always in proportion to the number
of procedures performed in a country, authors cannot
think of any group of surgeons with a strong interest in
the area that would be more or less likely to take part. It
provides several useful indicators for national societies
and IFSO to use for indicative purposes while
benchmarking individual bariatric procedures for their
membership. As expected, the majority of surgeons
viewed endorsements by their national societies and
IFSO as ‘very important’ or ‘extremely important’. This
must place additional responsibility on the office bearers
in these institutions to ensure that any evaluation follows
a scientific process.
Table 5 Outcome Measures for Study in Randomized Comparisons




Weight Loss 283 89.3 %
30-day morbidity and mortality 252 79.5 %
Longer term morbidity and mortality 258 81.4 %
Impact on co-morbidities like Type 2
Diabetes Mellitus
273 86.1 %
Quality of Life of Patient 265 83.6 %
Cost Effectiveness 180 56.8 %
Any other outcome measure(s) 44 13.9 %
Table 6 Some Other Interesting Comments (Edited)
The quality of the studies is more important than quantity.
Studies should be carried out in different geographical areas separately.
Even many existing procedures have not been evaluated fully yet.
The IRB is a local thing and varies from country to country. What some consider experimental others do not.
Societies should have a technical committee to assess the technical and historical aspects of new procedures, and if not very different from existing ones,
it should be cleared for faster acceptance.
I think we need to differentiate procedures that are very similar and use the same concepts of gastric reduction and small bowel shortening from those that
use other mechanisms.
I do not believe that organizations such as the ASMBS or IFSO should ‘endorse’ procedures. I do not feel that organizations should be regulatory, but
advisory to its members and society.
It is important to consider if a new procedure can have dangerous implications.
RCT is important to standardize the new procedure, but not perform it.
I would like to see the endoscopic bariatric procedures included in the comparative studies with other surgical procedures.
The duration of recommended follow-up will depend on the likely timing of anticipated or potential adverse outcomes
I think it’s really important that IFSO regulates this. There are a lot of surgeons inventing new procedures with no or little regulations.
The procedure to be compared against depends on the nature of the new procedure.
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In the absence of any established criteria, the process has
thus far been somewhat arbitrary with potential for conflict of
opinion amongst the societies themselves. For example,
though One Anastomosis (Mini) Gastr ic Bypass
(OAGB/MGB) is listed as an accepted procedure on the
IFSO website [7] and there is a position statement approved
by British Obesity and Metabolic Surgery Society in the
United Kingdom [8], many other national societies including
Table 7 A Brief Questionnaire with Summary of Responses
Questions Responses
Please confirm that you are a bariatric
metabolic surgeon
Yes (396/422) No (26/422)
Which Country Do you Work In? Respondents were provided with a complete list of all the countries. Data summarized in Table 1
Are you a member of the IFSO? Yes (337/396; 85.5 %) No (59/396; 14.5 %)
Are you a member of a national bariatric
society affiliated to the IFSO?
Yes (378/395; 95.7 %) No (17/395; 4.3 %)
For a new bariatric/ metabolic procedures,
what in your opinion is the minimum
number of studies required under the
careful monitoring of an IRB before it
can be regarded as an accepted
treatment option.
Responses summarized in Table 2
For a new bariatric/ metabolic procedures,
what in your opinion is the minimum
number of patients it must be
performed on under the careful
monitoring of an IRB before it can be
regarded as an accepted treatment
option.
Responses summarized in Table 3
For a new bariatric/ metabolic procedures,
what in your opinion should be the
minimum follow up documented under
the careful monitoring of an IRB before
it can be regarded as an accepted
treatment option.
Responses summarized in Table 4
How important is the endorsement of a
new surgical procedure by your
national society to you?
Responses summarized in Fig. 1
How important is the endorsement of a
new surgical procedure by the IFSO to
you?
Responses summarized in Fig. 2
Should every new procedure be examined
in a randomized trial setting against
one of the existing procedures?
Yes (294/395; 74.4 %) No (62/395; 15.7 %) Not Sure (39/395; 9.9 %)
Which procedure must every new
procedure be examined against in
randomized setting (If answer to













How many such Randomized Controlled
Trials comparing the new procedure
with one of the existing procedures
would you like to see before a new
procedure becomes an acceptable
option?










Which Outcome Measures must be
included in any comparative analysis in
your opinion?
Responses summarized in Table 5
Do you wish to share any other thought
relevant to this survey?
Key comments developed in Results section and other important ones summarized in Table 6
Do you Consider yourself a Key Opinion




Yes (139/385; 36.1 %) No (165/385; 42.8 %) Not Sure (81/385; 21.0 %)
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the American Society for Metabolic and Bariatric Surgery [9]
do not currently include it in their list of bariatric surgical
procedures.
The requirement of 5 clinical studies on 500 patients with
5 years follow-up, as well as the need for randomized com-
parisons, would appear reasonable and adequate to most bar-
iatric and metabolic surgeons. Though majority of the sur-
geons indicated that they would like to see at least 4–5 such
randomized comparisons, one has to bear in mind this proba-
bly indicates the ground reality when most current random-
ized clinical trials involving the discipline have small sample
sizes [10, 11]. In this context, even one large multicentre trial
should be acceptable. Several respondents highlighted this
point. IFSO and national societies could play a role in orga-
nizing such trials.
Though, the findings of this survey could only realistically
apply to future procedures, they might also allow for better
benchmarking in areas of current clinical controversy [12] and
difference of opinions. Similarly, though this survey focuses
on bariatric surgical procedures, it cannot be impossible to
come up with indicative numbers for endoscopic procedures.
This survey focuses on defining criteria for new bariatric
procedures rather than technical modification or improvisa-
tion of existing ones [13]. Though the definition of what
should constitute a new procedure itself can be arbitrary [14,
15] and has been one of the biggest stumbling blocks in de-
veloping a clear framework for surgical innovation, generally
if an operation is different enough from the existing alterna-
tives to need a new name, it could safely be categorized as a
new procedure. At the same time, one recognizes that major
alterations in even existing procedures itself should probably
go through a process of closer monitoring. At the very least,
there should be an expectation that surgeons document their
variation, audit their results and share the findings with others.
Similarly, when surgeons are developing a new approach (i.e.,
robotic or natural orifice) for an existing operation, it is likely
that a different set of rules will be required – those that pri-
marily govern the safety of that approach in general and spe-
cifically for the procedure under consideration.
It has been suggested [16] that it is incumbent upon bariat-
ric surgeons to ‘compare and contrast’ the new technology and
procedures against the ‘standards of care’. In this survey too,
most respondents felt every new procedure should be exam-
ined against one of the existing alternatives in a randomized
setting. Most surgeons felt RYGB (n = 267, 84.2 %) and SG
(n = 174, 54.9 %) were most suitable for such comparisons.
It is also worth pointing out only two surgeons in this
survey felt that appropriate animal models should be devel-
oped first before human trials are conducted. Indeed, it is not
easy to carry out animal research in accordance with the
ARRIVE guidelines [17] and the findings may well not be
extrapolatable to human populations. At the same time, devel-
opment of appropriate animal models of bariatric procedures
is necessary to understand the underlying mechanisms and
physiology [18, 19] and facilitate the development of less
invasive treatment options in the future. This does not, how-
ever, have to happen before the procedure is introduced into
routine clinical practice but may be advisable.
There are several weaknesses to this survey. It is a survey of
bariatric surgeons on bariatric surgical procedures. The find-
ings cannot hence be extrapolated to other surgical procedures
and other (endoscopic) bariatric procedures. This survey is
specific to bariatric surgeons.
Since the link to the survey was widely popularized, we are
unable to define a response rate for our survey. However,
authors cannot think of any possible bias as a result of it
especially because of its relatively large sample size. The sur-
vey was conducted in English language and hence excludes
non-English speaking surgeons. This problem is however not
confined to this survey and can also be traced to other areas of
scientific communications.
Patient safety and innovation are not mutually exclu-
sive. The pace, as well as the acceptability of any surgical
innovation, can be enhanced if there are appropriate
mechanisms in place. Clearly-defined processes and pro-
cedures will enable innovators and protect patients. This
survey should be seen as an attempt to understand the
popular opinion of bariatric surgeons on what constitutes
an experimental or new procedure and at what stage can a
procedure be recommended for inclusion into mainstream
clinical practice. Individual procedures will have unique
characteristics that will demand modification of these
criteria. The findings of this survey should hence only
be used for the purposes of guiding authoritative commit-
tees of national and international societies, and for future
consensus building exercises. It is worth emphasizing the
difference between a survey and a consensus statement
here [20]. This survey of bariatric surgeons does not at-
tempt to build a consensus. Any consensus building exer-
cise will necessarily have to start with identifying a mul-
tidisciplinary group of experts with an interest in this area
followed by adoption of an agreed modified Delphi pro-
tocol [20]. There is no reason why that cannot be the next
step for the bariatric community in this difficult area.
It is possible that the opinions expressed in this survey
were influenced by the choices offered. The choices were
however constructed by the authors as the most logical
options for each question. Moreover, respondents were
allowed to disagree with the choices offered through the
provision of a free text box to enter ‘other’ choices.
Authors would also like to caution against over-
interpretation of survey findings. The findings of this sur-
vey should simply form a starting point of discussion in
this somewhat controversial and difficult area of debate.
They are not meant to influence ground reality until an
international consensus can be reached amongst experts.
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Conclusion
Most bariatric surgeons feel that any new bariatric procedure
must first be evaluated in at least 5 clinical studies, conducted
under the strict monitoring of Institutional Review Boards, on
500 or more patients with minimum documented follow-up of
5 years. Majority also felt the need for randomized compari-
sons with one of the existing alternatives like Roux-en-Y
Gastric Bypass or Sleeve Gastrectomy. At the same time, we
must be cautious in interpreting the findings of a grassroots
survey like this. The findings of this survey are simply aimed
at starting a discussion on this topic and cannot be used to
influence the ground reality until an international consensus
can be reached amongst experts.
IFSO, International Federation for the Surgery of Obesity
and Metabolic Disorders; ASMBS, American Society for
Metabolic and Bariatric Surgery; IRB, Institutional Review
Board; OAGB/MGB, One Anastomosis (Mini) Gastric
Bypass; RYGB, Roux-en-Y Gastric Bypass; SG, Sleeve
Gastrectomy; GB, Gastric Banding.
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